方盛制药：受让复方醋酸地塞米松乳膏药品上市许可

Core Viewpoint - Fangsheng Pharmaceutical has signed a technology transfer contract with Liaoning Yifan Pharmaceutical to acquire the marketing authorization for "Compound Dexamethasone Acetate Cream," which is primarily used for localized itching and neurodermatitis. This acquisition is expected to expand the company's dermatological product line and provide a new profit growth point [1]. Company Summary - Fangsheng Pharmaceutical (603998.SH) has entered into a contract for the transfer of technology and trade secrets, specifically acquiring the marketing rights for a dermatological product [1]. - The transaction amount falls within the approval authority of the company's chairman, thus does not require board or shareholder approval [1]. - The completion of this acquisition is anticipated to effectively enhance the company's portfolio in skin disease medications [1].